Key result
The most common symptoms of chemotherapy-related cardiotoxicity in breast cancer patients were dyspnea, chest pain, peripheral edema, fatigue, and palpitations, with dyspnea characteristic of trastuzumab and chest pain characteristic of capecitabine.
Why the study?
Chemotherapy-related cardiotoxicity is a major cause of morbidity, prompting this study to provide in-depth information on its symptoms by exploring literature reporting types and symptoms in breast cancer patients.
What are the characteristic symptoms and timing of chemotherapy-related cardiotoxicity in patients with breast cancer?
Systematic Review (n=29)
What are the characteristic symptoms and timing of chemotherapy-related cardiotoxicity in patients with breast cancer?
Chemotherapy-related cardiotoxicity in breast cancer presents with specific, regimen-dependent symptoms (e.g., dyspnea with trastuzumab, chest pain with capecitabine) at varying times, highlighting the need for targeted symptom assessment tools.
Answers are grounded in this paper and cite their sources.
May inform symptom monitoring in breast cancer patients on chemotherapy; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Chemotherapy-related cardiotoxicity is a significant concern because it is a major cause of morbidity. This study aimed to provide in-depth information on the symptoms of chemotherapy-related cardiotoxicity (CRCT) by exploring literature that concurrently reports the types and symptoms of CRCT in patients with breast cancer. METHODS: A scoping review was performed according to an a priori protocol using the Joanna Briggs Institute's guidelines. The participants were patients with breast cancer. The concept was the literature of specifically reported symptoms directly matched with CRCT and the literature, in English, from 2010, and the context was open. The search strategy included four keywords: "breast cancer," "chemotherapy," "cardiotoxicity," and "symptoms." All types of research designs were included; however, studies involving patients with other cancer types, animal subjects, and symptoms not directly related to CRCT were excluded. Data were extracted and presented including tables and figures. RESULTS: A total of 29 articles were included in the study, consisting of 23 case reports, 4 retrospective studies, and 2 prospective studies. There were no restrictions on the participants' sex; however, all of them were women, except for one case report. The most used chemotherapy regimens were trastuzumab, capecitabine, and doxorubicin or epirubicin. The primary CRCT identified were myocardial dysfunction and heart failure, followed by coronary artery disease, pulmonary hypertension, and other conditions. Major tests used to diagnose CRCT include echocardiography, electrocardiography, serum cardiac enzymes, coronary angiography, computed tomography, and magnetic resonance imaging. In all case reports, CRCT was diagnosed through an incidental checkup according to the patient's symptom presentation; however, only 10 of these studies showed a baseline checkup before chemotherapy. The five most common CRCT symptoms were dyspnea, chest pain, peripheral edema, fatigue, and palpitations, which were assessed by patient-reported symptom presentation rather than using a symptom assessment tool. Dyspnea with trastuzumab treatment and chest pain with capecitabine treatment were particularly characteristic. The time for first symptom onset after chemotherapy ranged from 1 hour to 300 days, with anthracycline-based regimens requiring 3-55 days, trastuzumab requiring 60-300 days, and capecitabine requiring 1-7 days. CONCLUSIONS: This scoping review allowed data mapping according to the study design and chemotherapy regimens. Cardiac assessments for CRCT diagnosis were performed according to the patient's symptoms. There were approximately five types of typical CRCT symptoms, and the timing of symptom occurrence varied. Therefore, developing and applying a CRCT-specific and user-friendly symptom assessment tool are expected to help healthcare providers and patients manage CRCT symptoms effectively.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) conducted a systematic review in Breast cancer with chemotherapy-related cardiotoxicity (n=29). Chemotherapy (anthracyclines, HER2 blockers, antimetabolites) was evaluated on Symptoms of chemotherapy-related cardiotoxicity. The most common symptoms of chemotherapy-related cardiotoxicity in breast cancer patients were dyspnea, chest pain, peripheral edema, fatigue, and palpitations, with dyspnea characteristic of trastuzumab and chest pain characteristic of capecitabine.
Synapse has enriched 10 related papers. Consider them for comparative context: